Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (Nasdaq: QTRX) will report its third quarter 2026 financial results before a conference call on November 9, 2026. The call will begin at 8:30 AM ET, with a live webcast available through the Investors section of the company website. An archived webcast replay will remain available for one year.
Quanterix (QTRX) and Innovita announced Chinese regulatory approvals for Quanterix instruments and neurology biomarker testing under their commercialization arrangement.
Innovita received National Medical Products Administration (NMPA) approval for Quanterix’s HD-X and SR-X instruments and testing kits for p-Tau 217, GFAP, p-Tau 181 and NfL. The arrangement, formed in 2024, combines Quanterix’s biomarker detection technology with Innovita’s diagnostic development, regulatory and commercialization capabilities in China. The approvals broaden the SIMOA-powered neurology testing portfolio available in that market.
Innovita plans regulatory submissions for additional Quanterix biomarker diagnostic kits in China. It may also expand into additional neurodegenerative diseases and infectious diseases, extending the potential applications of SIMOA-powered diagnostics.
Quanterix (QTRX) has released its PhenoCode 2.0 Molecular Barcoding Kit globally, moving the product beyond early access.
The kit lets researchers barcode antibodies to extend existing panels. The TIME panel, a PhenoCycler-Fusion module compatible with the PhenoCode Discovery IO60 panel, is on track to ship in Q4 2026. Shipment of a second IO60-compatible module, the high-plex ADC panel, is confirmed for the same quarter; it measures ADC target expression alongside tumor immune context in one tissue section. Quanterix's Accelerator Laboratory is also accepting requests to develop custom ADC panels for biopharma and translational teams.
Quanterix (QTRX) granted equity-based inducement awards on September 15, 2026 to new hires, including Chief Commercial Officer James Gute, under Nasdaq Listing Rule 5635(c)(4).
Gute received an inducement grant of 260,315 restricted stock units (RSUs), representing the same number of common shares. Two other employees received a combined 365,326 RSUs, also representing 365,326 common shares. All RSUs vest in four equal annual installments on the first four anniversaries of the grant date, contingent on each recipient’s continued employment with Quanterix or its subsidiaries. The awards were issued under the Quanterix Amended and Restated 2025 Inducement Plan and were approved by the Board’s Compensation Committee as a material inducement to the employees’ commencement of employment.
Quanterix (QTRX) appointed physician executive Dr. Yuri Fesko as Chief Medical Officer, providing medical and clinical leadership across the company.
He will work closely with Diagnostics, Scientific, R&D, Regulatory, and Commercial teams to support the broader market launch of the Lucent AD® Complete five‑biomarker Alzheimer’s disease test and help advance the IVD filing for the HD-X instrument. The company said his experience at a large diagnostics organization, and expertise in precision medicine across oncology, metabolic disease, neurology and consumer health, will help expand Quanterix’s diagnostics business and clinical impact. Dr. Fesko will be based at Quanterix’s Billerica, Massachusetts headquarters.
Quanterix (Nasdaq: QTRX) has appointed experienced healthcare executive Jim Gute as Chief Commercial Officer, based at its Billerica, MA headquarters. He is charged with leading a re-acceleration of growth in commercial operations as the company prepares to expand its diagnostics business and strengthen its core offerings.
According to Quanterix, Gute brings about 20 years of senior commercial leadership, including roles as President of GE Healthcare and Senior Vice President and Commercial Manager, General Screening, at Exact Sciences, a company with nearly $3 billion in revenue prior to its acquisition by Abbott Labs in early 2026.
Quanterix (NASDAQ: QTRX) reported second quarter 2026 revenue of $32.9 million, up 34% year over year, with GAAP gross margin of 38.5% and non-GAAP gross margin of 47.9%. Adjusted EBITDA loss was $10.0 million, an improvement from a $13.7 million loss a year ago. The company ended the quarter with $96.9 million in cash, cash equivalents, marketable securities, and restricted cash, and adjusted cash usage was $4.0 million.
Quanterix completed its ERP integration from the Akoya acquisition, achieving $85 million in annualized savings, but recorded a $26.9 million goodwill impairment related to Akoya. Leadership additions included a new Chief Commercial Officer, COO, CFO, and Diagnostics GM. In Alzheimer’s, Anthem Blue Cross and Blue Shield began covering qualifying blood-based biomarker tests, including Lucent AD® Complete, and new clinical data supported the company’s multi-analyte approach. Quanterix was also selected as a co-investigator in the PD-BUILD Parkinson’s biomarker program and launched new Simoa and spatial products.
For 2026, Quanterix now expects revenue of $142–$148 million (down from $169–$174 million), non-GAAP gross margin of 48–50% (previously 49–53%), cash flow breakeven in 2027, and a year-end 2026 cash balance of about $80 million, with no debt.
Quanterix (Nasdaq: QTRX) announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. CEO Everett Cunningham will join a webcast fireside chat at 1:00 pm ET on August 12, providing a company and strategic update.
Chief Technology and Product Officer Michael Miller will join a Neurology Diagnostics panel at 2:00 pm ET the same day. Quanterix is also arranging one-on-one investor meetings involving Cunningham, CFO Jason Faessler and Miller. The live webcast and replay will be available via the company’s Investor Relations website.
Quanterix (Nasdaq: QTRX) will hold a conference call on Monday, August 10, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results. According to Quanterix, a press release with these results will be issued earlier that day and posted on its website.
Investors may join the call via USA & Canada toll-free dial-in (800) 715-9871 or (646) 307-1963 using conference ID 9896910, or listen through a live webcast in the Investors section of the Quanterix website. An archived webcast replay will be available for one year.
Quanterix (NASDAQ: QTRX) reported that on July 15, 2026, it made an inducement equity grant to Jason Faessler in connection with his commencement as Chief Financial Officer and Treasurer. The award consists of 141,820 restricted stock units (RSUs), each representing one share of Quanterix common stock.
According to Quanterix, the RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the company or its subsidiaries. The grant was made under the Amended and Restated 2025 Inducement Plan as an inducement material to entering employment, in line with Nasdaq Listing Rule 5635(c)(4), and was approved by the Board’s Compensation Committee.